
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc. demonstrated improved financial performance in its 2Q25 results, with a recorded net loss of $1.14 per share, which was narrower than the prior estimate of $1.22 per share. The company’s lead drug candidate, OKI-219, has shown promising safety results, being well-tolerated at all dose levels and reporting only Grade 1 treatment-related adverse events without any serious complications. These advancements in clinical outcomes, coupled with a better-than-expected financial report, contribute to a favorable outlook for the company's stock.
Bears say
OnKure Therapeutics Inc. is anticipated to experience a full-year 2025 net loss of $4.56 per share, which reflects a slight improvement over the previous estimate of $4.75 per share. However, several significant risks contribute to a negative outlook, including potential negative clinical results from the lead asset, OKI-219, and possible delays in advancing pipeline candidates to critical regulatory stages. Furthermore, the company faces challenges related to obtaining timely regulatory approvals and intense competition from other therapies, which may result in long-term dilution risks for investors.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares